Our virtual panels include over 3,000 genes selected based on the most up-to-date literature, gene reviews and variant databases. Our whole genome approach offers cost-effectiveness by reducing the need for multiple targeted tests, and maximises diagnostic yield by allowing you to combine panels, select individual genes, and surface variants across all regions of the genome.
Genetic panel tests can aid in the diagnosis of various hematologic disorders, including thalassemias, sickle cell disease, and various types of anemias. These tests can identify specific genetic mutations responsible for these conditions, helping clinicians confirm diagnoses and tailor treatment plans.
In the case of hematologic malignancies such as leukemia, lymphoma, and myeloma, genetic panel tests can provide prognostic information. Identifying specific genetic mutations or rearrangements can help predict disease progression, response to treatment, and overall patient outcomes.
While genetic panel tests are highly valuable in hematology, it’s essential to interpret their results in the context of a patient’s clinical presentation and other diagnostic tests. We recommend working closely with genetic counselors and other specialists to ensure that genetic information is used effectively to diagnose, treat, and manage hematologic conditions.
For further information on tailoring treatment plans to an individual’s genetic profile, leading to improved outcomes and reduced side effects, please visit our pharmacogenomics page.